CURRENT STATUS
GLP-1 agonists (semaglutide/Wegovy, tirzepatide/Mounjaro) achieving 15–25% weight loss. Next-gen triple agonists in trials. AI discovering new metabolic targets beyond GLP-1. Gene variants in MC4R, FTO, and POMC pathways being targeted.
KEY BREAKTHROUGHS
Semaglutide (Wegovy/Ozempic) — GLP-1 agonist achieving ~15% sustained weight loss
Tirzepatide (Mounjaro/Zepbound) — dual GIP/GLP-1 agonist achieving ~22% weight loss
Amgen MariTide — monthly injection GLP-1/GIP dual antagonist in Phase II
Retatrutide — triple agonist (GLP-1/GIP/glucagon) showing 24% weight loss in Phase II
AI-COMPRESSED PIPELINE
AI TOOLS ACCELERATING CURES
Metabolic Pathway AIGut Microbiome AnalysisPrecision Nutrition ModelsAppetite Circuit Mapping
KEY ORGANIZATIONS
Novo NordiskEli LillyAmgenStructure TherapeuticsFractyl Health
TIMELINE ESTIMATE
Oral GLP-1s: 1–2 years. Gene therapy for monogenic obesity: 4–6 years. Full metabolic reprogramming: 6–10 years.